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Abstract Recently, there has been a renewed interest in the natural-products-inspired drugs. Quebrachitol (QCT) is one of
naturally occurring optically active cyclitols that has now received considerable attention. Until the last decade, it came to
be a starting point for the lead discovery. In this review, we had a discussion on the basic research of QCT, including its
source, structure, properties, and the recent advances on its application. The biological activities and QCT-inspired leads
that are potentially effective for treating human diseases were also discussed.
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1 Introduction
For many years, natural products have been the inspiration
and an essential source for medicinal chemistry and drug
discovery. An analysis of all therapeutic agents that have
been approved byUSFDA from1981 to 2014 reveals that the
natural products and their frameworks continuously play a
profound impact on the medicinal chemistry [1]. Over
34 years, total 1562 drugs have been approved. Those clas-
sified as ‘‘Synthetic drug’’ category have the largest pro-
portion, with 52%. The next is the natural product and its
subdivision (‘‘Natural product botanical drug’’ and ‘‘Derived
from a natural product’’), which account for 26%, followed
by 22% being ‘‘Vaccine’’ or ‘‘Biological macromolecule’’.
Inspection of all approved drugs as shown in Table 1
demonstrates that medicinal chemists never cease exploring
the utilization of natural products for drug discovery. In 2004
only, 10 of 44 approved small molecule drugs are in the
categories of ‘‘Natural product’’, ‘‘Natural product botanical
drug’’ and ‘‘Derived from a natural product’’. Since the 2015
Nobel Prize for Physiology orMedicine was awarded to Drs.
Omura, Campbell and Prof. Tu, there has been a renascent
interest in not only the natural-product-related drugs, but also
in their enantioselective [2, 3]. Furthermore, the persistent
use of natural products, natural product derivatives and their
fragments could be anticipated, especially with the subse-
quent developments of computational tools, including
chemo- and bioinformatics approaches [4, 5]. Isolation from
natural sources is usually a primary approach to provide
natural products to complete biological studies and to dis-
cover and develop new drug candidates. Quebrachitol (2-O-
methyl-L-inositol) (QCT), a bioactive plant constituent, is
one of naturally occurring optically active cyclitols that has
received considerable attention as a starting point for lead
discovery. Therefore, in this article we discussed the basic
research of QCT, including its source, structure and prop-
erties. In addition, we gave an insight to the recent advances
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on its application, with a focus on its biological activities that
are related to human diseases.
2 The Source of QCT
QCT is the byproduct of the rubber industry. The discovery
history of QCT can be traced back to 1889, when it was
discovered by Tanret from the quebracho bark of Aspi-
dosperma quebracho for the first time. The concentration
in the aqueous phase (serum) of the latex of rubber trees
was reported to be 2%, and it was firstly obtained from this
source by de Jong in 1906. As a chiral building block, QCT
was further expanded by its availability in high concen-
trations from rubber tree. Then in 1932, QCT had been
prepared on a larger collection by Rhodes and Wiltshire
[6]. Afterwards, QCT was separated out of the red oil of
Minnesota Wild Hemp [7]. The first systematic method of
extracting QCT was reported by Jan van Alphen [6].
Because QCT is seldom coexisted with its isomer D-pinitol
in the same plant family, isolation from natural source
provides an excellent way to obtain pure compound. In
addition, QCT can be found in Allophylus edulis, Di-
pladenia martiana and Sapindus rarak [8–10]. It was the
active component of Cannabis sativa and sea buckthorn
[11]. QCT could also be extracted from the South African
plants enumerated hereunder: Artemisia afra Jacq., Car-
diospermum halicacabum L., and Paullinia pinata L.
Recently, QCT, identified as main constitutes in the flesh of
litchi, was deemed to be the important contribution to the
widely known health benefits of litchi [12].
3 The Structure and Properties of QCT
QCT, a colorless crystalline compound, melts at about
192–193 C and can be sublimed under a diminished
pressure. Its boiling point in vacuum is approximately
210 C. The spectral data and crystal structure results of
QCT were discussed by Patterson et al. in 1931, Huang
et al. in 1994 and Dowd et al. in 2002, respectively
[13–15]. QCT crystal was placed in the monoclinic system,
space group P21, with cell parameters a:b:c =
6.60:7.15:8.658, b = 90 and Z = 2. The refractive index
is na = 1.546, nb = 1.552, nm = 1.572. QCT can easily
dissolve in water, 100 g saturated solution containing 38 g
(0 C), 39 g (12 C), and 70 g (l00 C) of QCT. It is sol-
uble in boiling alcohol, acetic acid and in pyridine, but
insoluble in ether.
As illustrated in the Fig. 1, QCT, which is a methyl-
derivative of inositol, has similar physiological effects with
inositol. In eukaryotes, inositol, usually in the form of
phosphatidylinositol (PI), is a principle constituent of cell
membranes and is involved in multiple pivotal transmem-
brane signaling pathways [16]. The structure of QCT is
similar with glucose, but not in function. QCT would not
enhance the blood sugar level after it was taken. It is two or
three times less sweeter than cane sugar, but the edible
concentration may produce colic and diarrhea [17]. Owing
to this reason, Robert et al. recommended against using
QCT as a sweetening agent.
Table 1 Detailed information of all approved drugs from 1981 to
2014
V S/NM S*/NM S* ND NB N B S Total
1981 1 1 4 4 7 0 3 0 20 40
1982 0 0 2 0 7 0 3 5 14 31
1983 0 2 2 3 9 0 4 1 35 56
1984 0 2 2 2 14 0 1 1 22 44
1985 1 4 2 1 18 0 3 9 17 55
1986 1 3 4 0 13 0 3 6 26 56
1987 1 4 5 3 24 0 8 8 25 78
1988 0 6 6 2 16 0 6 2 24 62
1989 2 5 7 2 8 1 3 3 12 43
1990 1 3 7 0 10 0 1 6 18 46
1991 0 7 5 3 6 0 0 10 9 40
1992 1 2 2 3 13 0 2 9 14 46
1993 3 4 4 2 14 0 2 3 14 46
1994 1 5 3 2 13 0 2 8 13 47
1995 2 5 5 5 9 0 2 3 12 43
1996 2 8 8 2 7 0 1 10 12 50
1997 1 15 8 1 5 0 0 5 12 47
1998 2 10 5 1 9 0 0 9 8 44
1999 2 5 4 3 13 0 2 8 9 46
2000 7 3 7 2 12 0 1 3 12 47
2001 1 2 3 2 10 0 0 20 5 43
2002 1 8 4 2 12 0 0 3 8 38
2003 2 2 8 1 5 0 3 11 3 35
2004 2 2 3 2 7 0 0 4 4 24
2005 8 3 3 2 9 0 4 11 12 52
2006 9 10 1 3 3 1 1 10 2 40
2007 6 5 2 1 5 2 4 12 7 44
2008 6 4 4 1 8 1 0 8 6 38
2009 11 10 2 0 5 0 0 7 7 42
2010 6 6 0 0 8 0 1 7 5 33
2011 1 3 11 0 6 0 2 6 5 34
2012 9 6 9 2 6 2 2 16 8 60
2013 8 6 9 3 3 0 1 8 9 47
2014 3 11 11 1 6 2 2 18 11 65
Data from JNP [1]
B biological, usually a peptide or protein, N natural product,
unmodified in structure, NB natural product ‘‘botanical drug’’, ND
derived from a natural product, S totally synthetic drug, S* made by
total synthesis, but the pharmacophore is from a natural product,
V vaccine, NM natural product mimic
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4 The Regulation of QCT Absorption
QCT, together with sucrose, is one of the main sugars in the
latex of rubber trees. Nevertheless, the mechanisms of how
QCTwas absorbed remained to be elucidated in more detail.
To this end, Anaı¨s Dusotoit-Coucaud et al. investigated and
characterized the transporter of QCT from latex. A new
polyol transporter, HbPLT2, was identified which acted as a
plasma membrane H?/QCT symporter [18]. First, through
screening a latex cDNA library, two full length cDNAs were
isolated referred as to Hevea brasiliensis polyol transporter
1 and 2, respectively (HbPLT1 and HbPLT2). The two
transporters exhibited 89% identity at the protein sequence
levels and shared the main features of the previously cloned
acyclic sugar polyol transporters. In order to examine the
ability of HbPLT2 as a transporter, functional expression
was carried out in yeast strains. These strains could absorb
polyol but no absorption of sucrose and hexose. As a result,
the phenomenon that xylitol uptake was inhibited by an
excess of QCTwas observed, which suggested that QCTwas
a substrate of HbPLT2. In conclusion, their research gave
clues for the further investigations of QCT functions with
regard to the physiological features of rubber trees.
5 The Applications of QCT
According to above-mentioned properties, QCT could
serve as the starting material of inositol or its derivatives to
participate in several important pathways and may act as a
potential anticancer or antidiabetic drug lead to arrest or
reverse these diseases.
5.1 Effects of QCT on Diabetes Mellitus
Diabetes mellitus (DM), currently characterized by symp-
toms of chronic hyperglycaemia, is a syndrome defined as a
state of dysregulation of glucose homeostasis and lipid
metabolism due to beta cell dysfunction or insulin resis-
tance [19]. Although some success was achieved in low-
ering blood sugar, type 2 DM (T2DM) remains to be one of
the widespread epidemics. Hence, there is a compelling
need for discovering novel antidiabetic drugs. A growing
number of studies have shown the great potential of QCT
in the suppression of T2DM symptoms. Early in 1933,
Robert et al. investigated the effect of QCT as a sweetening
agent for diabetics [17]. Martina et al. isolated QCT from
A. edulis, which was used to treat diabetes in the practice of
local traditional medicine [8]. Yong Xue and coworkers
reported their study about the effects of sea buckthorn juice
and QCT on T2DM, in which db/db mice were fed with
pure sea buckthorn juice or sea buckthorn juice rich in
QCT for 10 weeks [20]. Their results manifested the
effects of sea buckthorn juice in lowering blood sugar
level, possibly concerned in the improvement of pancreas
function and reversal of insulin resistance. Moreover, QCT
was used to synthesize b-glucosidase inhibitors while tar-
geting gluconeogenesis or glucose homeostasis was sug-
gested to be a new strategy for developing more efficient
DM therapeutics [21]. Thereby, QCT or its derivatives
could be used as a potential antidiabetic medicine even
though further research was required to improve the
effectiveness.
5.2 Effects of QCT on Inhibiting PAFR
Platelet-activating factor (PAF), a metabolite of arachi-
donic acid pathway, features prominently in cell prolifer-
ation, migration and angiogenesis. Results from previous
studies indicated that its expression was elevated in several
cancers, such as human thyroid cancer, meningiomas,
breast cancer and oesophageal cancer [22–25]. Moreover,
recent study showed that PAF might play pivotal roles in



















Fig. 1 The structures of quebrachitol (a), inositol (b) and glucose (c)
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may be potentially effective for treating castration-resistant
prostate cancer (CRPC) [26].
The effects of QCT on inhibiting platelet aggregation
and PAF receptor (PAFR) were reported by Moharam et al.
[27]. Five compounds including QCT were first isolated
from the twigs of Mitrephora vulpina C.E.C. Fisch and
then evaluated for their inhibitory ability on PAFR binding
using 3H-PAF. Of all the compounds tested, phylligenin
and QCT stood out as the most potent inhibitors against
PAFR, with IC50 values of 13.1 and 42.2 lM, respectively.
The results of this study demonstrated the strong PAFR
inhibitory effect of phylligenin and QCT. QCT could
therefore be developed as a potential PAF antagonist, either
alone or combined with existing drugs, for the treatment of
CRPC.
5.3 Effects of QCT on Free Radical Scavenging
The maladjustment of reactive oxygen species production
and the endogenous antioxidants has been involved in the
pathogenesis of several obstinate diseases, such as cancer,
asthma, pulmonary hypertension, and retinopathy [28].
QCT was reported to prevent oxidative injury to diverse
pathways in various pathophysiological conditions.
Peroxynitrite (ONOO-) scavenging and laxative effects
of QCT have been reported in the previous study [29]. QCT
was also proposed to have free radical scavenging ability in
DPPH assay [30]. In 2006, Junior et al. pointed out that it
could inhibit 6-OHDA-induced generation of nitrogen
oxide in cultured mesencephalic cells [31]. The afore-
mentioned antioxidative effect of QCT may overcome the
oxidative stress and alleviate cellular dysfunction. In
addition to the effect of eliminating free radicals, being a
sugar-like molecule, QCT was likely to improve the
mitochondrial energy metabolism so that the 6-OHDA-in-
duced decrease of ATP could be prevented. Besides, as
describing on part 3, QCT closely resembles inositol in
structure, it can be used to synthesize PI, the main con-
stituent of cell membranes. It may also lower endoplasmic
reticulum stress response, which may be caused by
oxidative stress. Despite the fact that its mechanisms of
cytoprotection remained to be elusive, their research indi-
cated a clear antioxidant effect of QCT.
5.4 Effects of QCT on Gastroprotection
Studies suggested that nonsteroidal anti-inflammatory drug
(NSAID) or aspirin may cause gastrointestinal complica-
tions and sometimes even death [32, 33]. In 2008, the study
of Olinda et al. provided the first evidence that QCT has
gastroprotective effect against acute gastric lesions [34].
According to their research, QCT dramatically prevented
gastric lesions induced by ethanol and indomethacin at oral
doses of 12.5 and 25 mg/kg, which was mediated at least
partially by endogenous prostaglandins, nitric oxide release
and KþATP channel opening. In view of mucosal erosions
occurred after the administration of NSAID, QCT could
save stomach cells from injuries. Their finding was in well
agreement with that of Gharzouli et al., which reported that
in experiments with rats, the mannitol, glucose–fructose–
sucrose–maltose mixture and natural honey has the gas-
troprotective function against ethanol-induced gastric
damage [35]. In their previous work, QCT manifested an
antioxidant activity and a cytoprotective function in DPPH
assay and in rat fetal mesencephalic cells, respectively. In
this study, the evidence of cytoprotection against gastric
mucosal damage was offered [30, 31]. These researches
about gastroprotective role of QCT suggested that it could
be developed as a new therapy that combat the stomach
diseases arose from NSAID or aspirin use.
5.5 Effects of QCT on Synthesis
Natural products can be used as lead compound to generate
drugs with origin or novel therapeutic utility [36]. QCT
furnished an alternative optically structure for the con-
struction of compounds with specific biological activities.
In 1995, Kiddle gave an excellent perspective of the util-
ities of QCT in asymmetric synthesis [37]. As he sug-
gested, the particular advantage provided by QCT was that
there were no synthetic limitations imposed by the pres-
ence of a hemiacetal/ketal functionality. QCT, now as a
starting material, has been used to synthesize a variety of
biologically active compounds, most notably the inositol,
as listed in Table 2.
5.5.1 Synthesis of Natural Products Starting from QCT
Chida and coworkers have made valuable contributions to
the synthesis of biologically essential natural products,
starting from QCT. Two bislactones and one natural pro-
duct with antifungal activity were synthesized from QCT,
described by Chida et al. [38, 39]. The stereoselective
synthesis of the novel marine natural product, bengamide
A, B and E starting from QCT was later reported by them
[40, 41]. In 1997, Chida et al. proposed a strategy to syn-
thesize PA-48153C, a novel 2-pyranone derivative showed
potent immunosuppressive, cytotoxic and plant growth
regulator activities, utilizing QCT as a chiral building
block [42]. A year later, an effective synthetic pathway to
synthesize novel cerebrosides was put forward, using QCT
as a starting material as well [43]. Their synthetic studies
emphasized the validity of QCT as a chiral starting mate-
rial for the synthesis of optically active natural products.
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Table 2 Compounds with biological activities synthesized from QCT
Structures Activity Literature
A b-glucosidase inhibitor Akiyama et al. [44]
An inositol 1,4,5-trisphosphate 5-phosphatase and
3-kinase inhibitor
Liu et al. [48–50]
Bislactones, antifungal and antibacterial activities Chida et al. [38]
A IP3 5-phosphatase inhibitor (44, 0.3 lM) Liu et al. [49, 50]
A phosphatidylinositol synthase inhibitor (37%
inhibition)
Johnson et al. [53]
Antifungal activity Chida et al. [39]




Inhibit the grow of wild type NIH 3T3 cells by 30%
at 1 mM concentration
Kozikowski et al. [56]
A partial agonist at IP3 receptor
(EC50 = 1.14 ± 0.19 lM)
Liu et al. [51]
Anti-infectious activity Chida et al. [40]
Threefold less potent than IP3 on binding and Ca
2?
releasing activity
Kozikowski et al. [57]
Antibiotic, antitumor and immunosuppressive
activities
Barton et al. [46]




Immunosuppressive, cytotoxic and plant grow
regulator activities
Chida et al. [42]
Antitumor, immunostimulatory, neuritogenic and
growth inhibitory activities
Chida et al. [43]
A glycosidase inhibitor Falshaw et al. [45]
Synthesize PI(3, 4)P2, PI(4, 5)P2 and PI(3, 4, 5)P3 Qiao et al. [54]
Block the activation of the serine/threonine kinase
Akt
Kozikowski et al. [55]
Activation of IP3 receptor (Kd = 810 nM) Liu et al. [52]
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5.5.2 Synthesis of Antibiotics and Enzyme Inhibitors
Starting from QCT
Total synthesis of a variety of compounds with beneficial
effects were published in succession. In 1991, Akiyama
et al. reported a new strategy for the total synthesis of
cyclophellitol which is a b-glucosidase inhibitor through
Peterson olefination and demethylation, starting from QCT
[44]. Likewise, Falshaw used QCT as a starting material to
synthesize the inhibitors of b-glucosidase, which was
potential effective for the treatment of various disorders
and diseases such as diabetes, cancer, and AIDS [45].
Some other compounds, (-)-ovalicin and several related
analogues, with antibiotic, antitumor and immunosuppres-
sive activities were synthesized from QCT, proposed by
Barton et al. [46]. The work of Assis et al. described the
synthesis of inositol derivatives from QCT condensed with
2-mercaptobenzothiazole or 2-mercaptobenzimidazole,
which were potential antimicrobial agents [47].
Several researches made by Liu et al. were published
with regard to developing IP3 5-phosphatase inhibitors.
They sought to develop synthetic routines to inositol
phosphates and its analogues. Total synthesis from QCT to
the L-chiro-inositol 2,3,5-trisphosphate, which was a potent
IP3 5-phosphatase and 3-kinase inhibitor, was first reported
by them [48]. They proposed the synthesis of potent IP3
5-phosphatase inhibitors, L-chiro-inositol 1,4,6-trisphos-
phate, along with the corresponding trisphosphorothioate
and evaluated their potencies [49]. In 1992, Liu et al.
synthesized an inhibitor of the enzymes of 1D-myo-inositol
1,4,5-trisphosphate metabolism, using QCT as a starting
material [50]. They have also synthesized an analogue of
the second messenger, L-chiro-inositol 2,3,5-trisphospho-
rothioate, which was both a partial agonist in the release of
intracellular Ca2? and a lead compound for designing small
molecule IP3 receptor antagonists [51]. Moreover, Liu et al.
have designed a stable analog of IP3, 1D-2,3-dideoxy-myo-
inositol 1,4,5-trisphosphorothioate, which could be recog-
nized by IP3 receptor with a binding constant (Kd) of
810 nM [52].
Besides, a number of 3-substituted 1D-myo-inositols
were synthesized from QCT and evaluated as substrates for
PI synthase. Johnson et al. suggested that these compounds
could be used as probes for studying the PtdIns pathway
[53]. Due to the importance of PIPn’s in cell signaling,
Qiao et al. have designed a versatile approach to synthesize
PI(3, 4)P2, PI(4, 5)P2, and PI(3, 4, 5)P3 from QCT [54]. In
2002, Kozikowski et al. disclosed various modified PI
analogues, which could selectively inhibit serine/threonine
kinase Akt without decreasing the upstream kinase PDK-1
and other downstream kinases such as MAPK [55]. Above
studies suggested that these compounds, prepared by QCT,
were effective lead compounds for the development of
drugs designed to treat neoplastic diseases.
5.5.3 Synthesis of Inositol Derivatives Starting from QCT
Another aspect of QCT-inspired synthesis is inositols, espe-
cially on myo-inositol and its derivatives because of their
important role in multiple cell signaling pathways, such as
PtdIns(4, 5)P2 hydrolysis and PtdIns(3, 4, 5)P3 synthesis.
Additionally, these compounds may have potential thera-
peutic value. Kozikowski et al. synthesized and studied the
utilities of D-3-deoxy-3-phosphonomethyl-myo-inositol in
the PtdIns-30-kinase signaling pathway [56]. The results
showed that none of these compounds significantly inhibited
the growth of wild type and v-sis-transformed NIH 3T3 cells.
Then, they synthesized the novel 3-modified IP3 analogues,
lD-3-C-(trifluoromethyl)-myo-inositol 1,4,5-trisphosphate
and 1L-chiro-inositol 1,2,3,5-tetrakisphosphate. The prelimi-
nary results suggested that the proper modification of 3-po-
sition of IP3 may contribute to its binding with IP3 receptor
[57]. On the basis of studies mentioned above, Kozikowski
and co-workers have found that azido inositols, synthesized
from QCT could selectively inhibit the growth of v-sis-
transformed NIH 3T3 cells. Apart from these, Almeida et al.
have studied a simple route to synthesize some azido and
amino inositol derivatives, starting fromQCT [58]. In order to




Antimicrobial agents Assis et al. [47]
120 D. Wang et al.
123
chiro-inositol, which QCT was used as the original material,
has been accomplished by Barrs et al. [59].
The synthetic approaches previously described have
revealed that QCT has proven to be a useful optically
starting point for the construction of bioactive molecules.
5.6 Effects of QCT on Other Applications
Besides the applications mentioned above, some other
effects of QCT were described. Hewitt et al. had shown
that not only could QCT act as a phagostimulant for the
larvae, but may also supply the m-inositol dietary
requirements of the larvae, after conversion to m-inositol
[60]. In 2003, Akiyama et al., developed an enantioselec-
tive Michael addition of glycine imine using QCT as a
catalyst [61]. The study by Orthen et al. found that QCT
has the cryoprotective effect, as it could decrease mem-
brane damage to a similar degree as the two well-known
cryoprotectants, sucrose and trehalose [62]. Another liter-
ature reported the ability of membrane stabilization of
QCT, since it could improve structural and thermal sta-
bility for proteins [63].
6 New Direction of QCT in Multi-target Drug Design
Drugs that blocking a single pharmacological target are
often lack of effectiveness in controlling complex diseases,
such as diabetes, inflammation, cancer and central nervous
system disorders [64–66]. In order to treat these diseases
more effectively, the concept of combination therapy was
proposed. Combination drugs that using several com-
pounds to directly interact with multiple targets have been
employed [67–69]. However, a few problems would arise
in the combination of different drugs, including potential
drug–drug interactions and different pharmacokinetics
properties, which make the drug combination very com-
plicated. Accordingly, multi-target drugs, which could
interact with multiple targets simultaneously through one
compound, are prominent in the new drugs development
for the treatment of complex diseases. Currently, the multi-
target compound discovery techniques, namely the linker
strategy, framework combination and cross virtual
screening approach, have been developed. With the mani-
fold biological activities exhibited and the aforementioned
methods properly used, QCT may be potential multi-target
drug lead in treating DM and cancers.
7 Conclusions
In summary, we have given a brief overview of the
researches and the application of QCT. Currently, the
unclear macromolecular targets to act with, hampers the
rational design and further optimization of QCT. Accord-
ing to the literature reported before, QCT exerted its bio-
logical functions, by involving IP3 receptor, b-glucosidase,
PAFR, COX2, nitric oxide synthase, and KþATP channels.
Systematic identifying the molecular targets for on-target
and off-target effects of QCT, however, is still an important
and currently unmet challenge. It is conceivable that
through combinations of biochemical methods, genetic
interactions and computational inference, the working
mechanisms of QCT and its derivatives will be fully
understood.
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